Generic drugmakers tout competition bill as pressure builds to tackle drug costs

Modern Healthcare: The generic drug industry, responding to public anger over big price hikes for some generic products, is calling for action on a bipartisan Senate bill it says would increase the number of cheaper generic drugs and reduce U.S. drug spending.

Meanwhile, broader congressional efforts are building to hold both generic and brand-name drug manufacturers accountable for price spikes. Drugmakers would have to justify price hikes of 10% or more and disclose the information behind those pricing decisions under a separate bipartisan Senate bill called the Fair Drug Pricing Act.

Read article